← Back to Clinical Trials
Recruiting NCT06784466

Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

Trial Parameters

Condition Atrial Fibrillation (AF)
Sponsor Arga Medtech SA
Study Type INTERVENTIONAL
Phase N/A
Enrollment 360
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2025-09-10
Completion 2027-06
Interventions
Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System

Brief Summary

To evaluate the safety and effectiveness of the Argá Medtech CSE Ablation System in the treatment of atrial fibrillation.

Eligibility Criteria

Inclusion Criteria: 1. Patients between the ages of 18 and 80 years, or older than 18 if required by local law. 2. Diagnosis of drug refractory, recurrent, paroxysmal or persistent AF: a. Symptomatic paroxysmal AF that is less than 7 days in continuous duration, documented by the following: i. Physician documentation of symptomatic recurrent PAF (2 or more episodes) within 6 months prior to enrollment AND ii. At least 1 documented AF episode from any form of rhythm monitoring within 12 months prior to enrollment. b. Symptomatic persistent AF that is sustained beyond 7 days and less than 1 year (≥ 7 and ≤ 365 days), documented by the following: i. Physician documentation of at least 1 symptomatic persistent AF episode within 6 months prior to enrollment. ii. Either a 24-hour continuous ECG recording documenting continuous AF OR 2 ECGs from any regulatory cleared rhythm monitoring device showing continuous AF taken at least 7 days apart, within 6 months prior to enrollment. 3. Effectiven

Related Trials